Premium
P3‐235: THE LEVEL OF PLASMA Aβ IS CORRELATED WITH SLRP1 AND SRAGE IN ADULTS WITH NORMAL COGNITION: A POPULATION‐BASED CROSS‐SECTIONAL STUDY
Author(s) -
Gao Ling,
Qu Qiumin
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.1594
Subject(s) - glycation , medicine , apolipoprotein e , population , endocrinology , apolipoprotein b , linear regression , chemistry , receptor , lipoprotein , bayesian multivariate linear regression , cholesterol , disease , environmental health , machine learning , computer science
points at 1-year. Results: Fifteen (17.0%) participants had global cognitive decline. Demographics, comorbidities, baseline cognitive diagnosis (MCI/ mild AD/ moderate AD) and cognitive enhancer use were similar between progressors and non-progressors. At baseline, there was no difference in cognitive, ADL performance and neuropsychiatric symptoms between groups, although progressors were more impaired in iADLs (p1⁄40.008). Progressors had significantly greater deterioration in CMMSE [-3.6 (3.2) vs -0.6 (3.1), p1⁄40.002], worse ADL (p1⁄40.019) and iADL (p1⁄40.001), and higher NPI-severity score (p1⁄40.042) at follow-up. ApoE4 positivity, ARWMC and MTA scores were similar between groups. Serum inflammatory and endocrine biomarkers at baseline and 1year were similar between progressors and non-progressors. DKK-1 was significantly higher in progressors [1045.76 (553.84) vs 714.429 (366.85) ng/ml, p1⁄40.005]. After adjusting for age, gender and baseline CMMSE, elevated DKK-1 (top quintile) conferred significantly increased risk for global cognitive decline [OR1⁄43.62 (1.03-12.76), p1⁄40.045]. Conclusions:DKK-1 is a potential biomarker for identifying AD patients at risk of accelerated cognitive decline. DKK-1 neutralizing antibodies have demonstrated protective effects against synaptic loss in mouse models of AD. Our finding, if corroborated, supports DKK-1 as an alternative therapeutic target in AD.